Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2025 01:22 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical
November 13, 2025 17:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Third Quarter 2025 Results

Aptose Reports Third Quarter 2025 Results
November 03, 2025 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting
October 16, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
September 22, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML
August 22, 2025 17:01 ET | Source: Aptose Biosciences, Inc.

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor
August 18, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML
August 13, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Second Quarter 2025 Results

Aptose Reports Second Quarter 2025 Results
August 06, 2025 16:30 ET | Source: Aptose Biosciences, Inc.

Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy

• Safety Review Committee endorses escalation to 160 mg TUS dosing; no dose-limiting toxicities to date
August 01, 2025 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders

Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders